Market revenue in 2023 | USD 1,865.9 million |
Market revenue in 2030 | USD 2,223.7 million |
Growth rate | 2.5% (CAGR from 2023 to 2030) |
Largest segment | Viral vaccine |
Fastest growing segment | Bacterial Vaccine |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Viral Vaccine, Bacterial Vaccine, Combination Vaccine |
Key market players worldwide | GSK PLC, Johnson & Johnson, Pfizer Inc, Sanofi SA, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd, Bavarian Nordic A/S, Merck & Co Inc, AstraZeneca PLC, Emergent BioSolutions Inc, Novavax Inc, Inovio Pharmaceuticals Inc, Moderna Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to respiratory disease vaccine market will help companies and investors design strategic landscapes.
Viral vaccine was the largest segment with a revenue share of 54.84% in 2023. Horizon Databook has segmented the Canada respiratory disease vaccine market based on viral vaccine, bacterial vaccine, combination vaccine covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada respiratory disease vaccine market, including forecasts for subscribers. This country databook contains high-level insights into Canada respiratory disease vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account